Zusammenfassung
Hypereosinophile Syndrome sind eine heterogene Gruppe von Erkrankungen, die durch Bluteosinophilie und eosinophilenbedingte Organschäden gekennzeichnet sind. Sie erfordern eine umfassende Diagnostik, um die Grunderkrankung und Organbeteiligungen zu identifizieren, die wiederum die Prognose bestimmen. Insbesondere eine Herzbeteiligung ist als prognostisch ungünstig anzusehen. Teilweise lassen sich zugrunde liegende Entitäten gezielt behandeln, z. B. mit Tyrosinkinaseinhibitoren. In anderen Fällen kommt eine Glukokortikoidtherapie, in der Regel in Kombination mit steroidsparenden Medikamenten zur Anwendung. Zudem eröffnet das immer bessere Verständnis der molekularen Pathogenese neue, gezielte Therapieansätze wie den Einsatz von Zytokinantikörpern.
Abstract
Hypereosinophilic syndrome is a heterogeneous group of diseases characterized by blood hypereosinophilia and eosinophil-related organ damage. A comprehensive diagnostic work-up is necessary to identify underlying conditions and to detect organ involvement, which are important for prognosis. Involvement of the heart is related with a poorer outcome. Some underlying conditions can be treated with targeted therapies, e.g., tyrosine kinase inhibitors. However, glucocorticoids in combination with steroid-sparing drugs are generally used for treatment. Furthermore, the growing understanding of the molecular pathogenesis will lead to new therapies, e.g., the use of anti-cytokine antibodies.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Baccarani M, Cilloni D, Rondoni M et al (2007) The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRa-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 92:1173–1179
Bremer JP, Csernok E, Holle JU et al (o J) Getting rid of MPO-ANCA: a matter of disease subtype. Rheumatology (im Druck)
Comarmond C, Pagnoux C, Khellaf M et al (2012) Eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome) – clinical characteristics and long-term follow-up of the 383 patients enrolled in the FVSG cohort. Arthritis Rheum (im Druck)
Cools J, DeAngelo DJ, Gotlib J et al (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201–1214
Cortes J, Ault P, Koller C et al (2003) Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 101:4714–4716
Gleich GJ, Leiferman KM, Pardanani A et al (2002) Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359:1577–1578
Herrmann K, Gross WL, Moosig F (2012) Extended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndrome. Clin Exp Rheumatol 30(1 Suppl 70):S62–S65
Metzgeroth G, Walz C, Erben P et al (2008) Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase II study. Br J Haematol 143:707–715
Moosig F, Bremer JP, Hellmich B et al (2012) A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis (im Druck)
Moosig F, Gross WL, Herrmann K et al (2011) Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med 155:341–343
Moosig F, Richardt G, Gross WL (2012) Eosinophils and the heart: a fatal attraction. Rheumatology (im Druck)
Ogbogu PU, Bochner BS, Butterfield JH et al (2009) Hypereosinophilc syndromes: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 124:1319–1325
Rothenberg ME, Klion AD, Roufosse FE et al (2008) Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 358:1215–1228
Roufosse FE, Lavareille A de, Schandené L et al (2010) Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. J Allergy Clin Immunol 126:828–835
Schooley RT, Flaum MA, Gralnick HR (1981) A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations. Blood 58:1021–1026
Simon HU, Plötz SG, Dummer R et al (1999) Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 341:1112–1120
Vaglio A, Moosig F, Zwerina J (2012) Churg-Strauss syndrome: update on pathophysiology and treatment. Curr Opin Rheumatol 24:24–30
Valtent P, Klion AD, Horny AP et al (2012) Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 130:607–612
Weller PF, Bubley GJ (1994) The idiopathic hypereosinophilic syndrome. Blood 83:2759–2779
Wieczorek S, Holle JU, Bremer JP et al (2010) Contrasting association of a non-synonymous leptin receptor gene polymorphism with Wegener’s granulomatosis and Churg-Strauss syndrome. Rheumatology (Oxford) 49:907–914
Interessenkonflikt
Der korrespondierende Autor gibt für sich und seine Koautoren an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Moosig, F., Richardt, G., Merten, C. et al. Hypereosinophile Syndrome. Internist 54, 426–433 (2013). https://doi.org/10.1007/s00108-012-3189-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00108-012-3189-0